WO1998013007A2 - Procedes et compositions pour la lipidation de molecules hydrophile - Google Patents

Procedes et compositions pour la lipidation de molecules hydrophile Download PDF

Info

Publication number
WO1998013007A2
WO1998013007A2 PCT/US1997/017282 US9717282W WO9813007A2 WO 1998013007 A2 WO1998013007 A2 WO 1998013007A2 US 9717282 W US9717282 W US 9717282W WO 9813007 A2 WO9813007 A2 WO 9813007A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
disulfide
group
fatty acid
bbi
Prior art date
Application number
PCT/US1997/017282
Other languages
English (en)
Other versions
WO1998013007A8 (fr
WO1998013007A9 (fr
Inventor
Wei-Chiang Shen
Jinghua Wang
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Priority to EP97944483A priority Critical patent/EP1023316A4/fr
Priority to BR9712128-2A priority patent/BR9712128A/pt
Priority to CA002267179A priority patent/CA2267179A1/fr
Priority to AU45967/97A priority patent/AU737865B2/en
Priority to JP51593398A priority patent/JP2002515883A/ja
Priority to IL12917797A priority patent/IL129177A0/xx
Publication of WO1998013007A2 publication Critical patent/WO1998013007A2/fr
Publication of WO1998013007A9 publication Critical patent/WO1998013007A9/fr
Priority to NO991465A priority patent/NO991465L/no
Publication of WO1998013007A8 publication Critical patent/WO1998013007A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Definitions

  • the present invention relates generally to the fields of biology and medicine. More particularly, the present invention is directed to methods and compositions useful in increasing in mammals the absorption and retention of hydrophilic molecules, in particular peptides and proteins.
  • Such alternative routes may include the buccal, nasal, oral, pulmonary, rectal and ocular routes. Without exception, these routes are less effective than the parenteral routes of administration, but are still far more attractive than the parenteral routes because they offer convenience and control to the patients.
  • the oral route is particularly attractive because it is the most convenient and patient- compliant.
  • Mucosal barriers which separate the inside of the body from the outside (e.g. Gl, ocular, pulmonary, rectal and nasal mucosa), comprise a layer of tightly joined cell monolayers which strictly regulate the transport of molecules. Individual cells in barriers are joined by tight junctions which regulate entry into the intercellular space. Hence, the mucosa is at the first level a physical barrier, transport through which depends on either the transcellular or the paracelluiar pathways [Lee, V.H.L., CRC. Critical Rev. Ther. Drug Delivery Sys. , 5:69-97 (1988)].
  • the tight junctions comprise less than 0.5% of the total surface area of the mucosa [Gonzalez-Mariscal, LM. et a/., J. Membrane. Biol., 86:113-125 (1985); Vetvicka, V., and Lubor, F., CRC Critical Rev. Ther. Drug Deliv. Sys., 5:141-170 (1988)]; therefore, they play only a minor role in the transport of protein drugs across the mucosa.
  • transcellular transport of small drugs occurs efficiently provided the physiochemical properties of the drug are suited to transport across hydrophobic cell barriers.
  • the transcellular transport of proteins and peptides is restricted to the process of transcytosis [Shen, W.C., et al., Adv. Drug Delivery Rev., 8:93-113 (1992)].
  • Transcytosis is a complex process in which proteins and peptides are taken up into vesicles from one side of a cell, and are subsequently shuttled through the cell to the other side of the cell, where they are discharged from the endocytic vesicles [Mostov, K.E., and Semister, N.E., Cell, 43:389-390 (1985)].
  • the cell membrane of mucosal barriers is a hydrophobic lipid bilayer which has no affinity for hydrophilic, charged macromolecules like proteins and peptides.
  • mucosal cells may secrete mucin which can act as a barrier to the transport of many macromolecules [Edwards, P., British Med. Bull., 34:55-56 (1978)]. Therefore, unless specific transport mechanisms exist for protein and peptide, their inherent transport across mucosal barriers is almost negligible.
  • mucosal barriers possess enzymes which can degrade proteins and peptides before, after, and during their passage across the mucosa.
  • This barrier is referred to as the enzymatic barrier.
  • the enzymatic barrier consists of endo- and exopeptidase enzymes which cleave proteins and peptides at their terminals or within their structure. Enzymatic activity of several mucosa have been studied and the results demonstrated that substantial protease activity exists in the homogenates of buccal, nasal, rectal and vaginal mucosa of albino rabbits and that these activities are comparable to those present in the ilium [Lee, et al., (1988), supra]. Therefore, regardless of the mucosa being considered, the enzymatic barrier present will feature strongly in the degradation of the protein and peptide molecules.
  • the N and the C termini of peptides are charged and the presence of charged side chains imparts highly hydrophilic characteristics on these macromolecules.
  • the presence of charged side chains means that proteins and peptides have strong hydrogen bonding capacities; this H-bonding capacity has been demonstrated to play a major role in inhibiting the transport of even small peptides across cell membranes [Conradi, R.A., ef a/., Pharm. Res., 8:1453-1460 (1991)]. Therefore, the size and the hydrophilic nature of proteins and peptides combine to severely restrict their transport across mucosal barriers.
  • penetration enhancers One approach that has been used to alter the physical nature of the mucosal barriers is the use of penetration enhancers.
  • the use of penetration enhancers is based on the disruption of the cell barriers by low molecular weight agents which can fluidize cell membranes [Kaji, H., ef a/., Life ScL, 37:523-530 (1985)], open tight junctions [Inagaki, M., etal., Rhinology, 23:213-221 (1985)], and create pores in the cell membrane [Gordon, S., etal., Proc. Natl. Acad. Sci.
  • Protease inhibitors have been co-administered with proteins and peptides and have shown some limited activity in enhancing the abso ⁇ tion of these macromolecules in vivo [Kidro ⁇ , M., et al., Life Sci., 31:2837-2841 (1982); Takaroi, K., et al., Biochem. Biophys. Res. Comm., 137:682-687 (1986)]. The safety and the long term effects of this approach have yet to be thoroughly investigated.
  • the prodrug approach is based on the modifications of peptides in a manner that will protect them from enzyme degradation and recognition. This has been achieved by substitution of the D- forms of amino acids in the structure of peptides, the blockage of vulnerable groups on peptides by amidation and acylation, the inversion of the chirality of peptides, and the introduction of conformational constraints in the peptide structure.
  • the synthesis of prodrugs is only applicable to small peptides which have easily identifiable domains of activity.
  • Carrier ligands by virtue of their properties, can alter the cell uptake and transport characteristics of proteins and peptides.
  • the essence of this approach is that a cell-impermeant protein or peptide is covalently attached to a carrier which is highly transported into cells.
  • the mechanisms through which carrier ligands become endocytosed and transcytosed are important in deciding the suitability of the carrier for enhancing the transport of proteins and peptides.
  • Macromolecular carriers are hydrophilic and do not partition into the membrane. Therefore, the transport of large polymeric carriers into the cells is mediated by the affinity of the carrier for the cell membrane.
  • the uptake of a macromolecular conjugate starts with the binding to the cell membrane.
  • the binding of the carrier to the cells can be specific (e.g.
  • vesicles Once the carrier is bound to the cell surface, it is taken up into vesicles. These vesicles then become processed stepwise and can be routed to several pathways.
  • One pathway is the recycling of the vesicle back to the membrane from which it was invaginated.
  • Another pathway which is destructive to the conjugate, is the fusion with lysosomes.
  • An alternative pathway, and one which leads to the transcytosis of the conjugate, is the fusion of the vesicle with the membrane opposite to the side from which it was derived.
  • endocytosis determines the delivery of a protein conjugate to its target. For instance, endocytosis may determine the extent to which a conjugate is taken up by the target cell, but transcytosis determines whether or not a conjugate reaches its target [Shen, et al., (1992), supra]. For successful absorption through the Gl- tract, a conjugate must bind the apical membrane of the Gl-mucosa, become internalized into the mucosal cells, be delivered across the cells, and finally become released from the basolateral membrane
  • Fatty acids as constituents of phospholipids, make up the bulk of cell membranes They are available commercially and are relatively cheap. Due to their pidic nature, fatty acids can easily partition into and interact with the cell membrane in a non-toxic way Therefore, fatty acids represent potentially the most useful carrier ligands for the delivery of proteins and peptides Strategies that may use fatty acids in the delivery of proteins and peptides include the covalent modification of proteins and peptides and the use of fatty acid emulsions
  • fatty acid derivatives of sulfhydryl- or disulfide- containing compounds for example, peptides, proteins or oligonucleotides which contain or are modified to contain sulfhydryl groups
  • fatty acid-conjugated products with disulfide linkage(s) are employed for delivery of the sulfhdryl- or disulfide-containing compounds to mammalian cells.
  • This modification markedly increases the absorption of the compounds by mammalian cells relative to the rate of absorption of the unconjugated compounds, as well as prolonging blood and tissue retention of the compounds.
  • the disulfide linkage in the conjugate is quite labile in the cells or in vivo and thus facilitates intracellular or extracellular release of the intact compounds from the fatty acid moieties.
  • Reagents and methods for preparation of the fatty acid derivatives are also provided.
  • Fig. 1 is a bar graph illustrating the uptake of BBI, BBIssPal and BBIssOleic in Caco-2 cells;
  • Figs. 2A-2D are graphs which illustrate the biodistribution of BBI and BBIssPal in blood, kidneys, lungs and liver of CF-1 mice following iv-administration;
  • Figs. 3A-3D are graphs which illustrate the biodistribution of BBI and BBIssOleic in blood, kidneys, lungs and liver of CF-1 mice following iv-administration;
  • Figs. 4A-4C are bar graphs which illustrate the biodistribution of BBI and BBIssPal in CF-1 mice following ip-administration;
  • Figs. 5A and 5B are a graph and bar graph, respectively, which illustrate the transcytosis and accumulation of BBI, BBIssPal(2) and BBIssPal(4) across and into Caco-2 cells;
  • Fig. 6 is a graph which illustrates the results of Sephadex® G50 gel filtration analysis of basal medium from Caco-2 cells containing transcytosed BBI, BBIssPal(2) and BBIssPal(4).
  • Figs. 7A and 7B are graphs which present the effects of subcutaneously administered DP and DP-P on rats with diabetes insipidus, at a dose of 3.3 ⁇ g/kg: (7A) illustrates the urine output, (7B) illustrates the water intake.
  • Fig. 8 is a graph which compares the efficacies of DP and DP-P as a single subcutaneous injection for the treatment of rats with diabetes insipidus at different doses.
  • Fig. 9 is a graph which compares the structure-activity relationship of desmopressin-fatty acid conjugates in relation to the chain length of the fatty acid, at a dose of 0.5 ⁇ g/kg subcutaneous injection.
  • C-6 denotes caproic acid
  • C-10 denotes capric acid
  • C-16 denotes palmitic acid
  • C-18 denotes stearic acid.
  • Fig. 10 is a graph which illustrates plasma desmopressin profiles following intravenous administration of desmopressin (DP) or its palmitic acid conjugate (DP-P) in mice.
  • DP desmopressin
  • DP-P palmitic acid conjugate
  • Figs. 11A and 11B are graphs which illustrate the plasma calcitonm and calcium levels following subcutaneous administration of calcitonin (CT) or its palmitic acid conjugate (CT-P) in mice, at a dose of 100 ⁇ g/kg, (11A) illustrates the CT-P treatment; (11B) illustrates the CT treatment.
  • CT calcitonin
  • CT-P palmitic acid conjugate
  • a sulfhydryl-containing compound for example, a biopolymer as hereinafter defined
  • a fatty acid derivative via a reversible, biodegradable disulfide bond.
  • Such a conjugate would be expected to bind to the apical side of a cell membrane, reach the basolateral membrane of the Gl-epithelium as a result of membrane transport and turnover, and may become released into interstitial fluid as the result of disulfide bond reduction.
  • P is a residue derived from a sulfhydryl-containing compound
  • R 1 is hydrogen, lower alkyl or aryl
  • R 2 is a hydrophobic substituent (as hereinafter defined)
  • R 3 is hydroxy, a hyrdophobic substituent or an amino acid chain comprising one or 2 amino acids and terminating in -C0 2 H or -COR 2 .
  • a conjugate of general formula VI is formed from the sulfhydryl- containing compound and the conjugate is then administered to the mammal (for example, as part of a pharmaceutical composition, e.g. in an aqueous solution or an oral dosage unit) wherein the conjugate is administered in an amount effective to acheive its intended purpose.
  • A is an aromatic activating residue (as hereinafter defined) and R 1 , R 2 and R 3 are as previously defined.
  • the compounds of general formula V are particularly useful in preparation of conjugates of general formula VI from sulfhydryl-containing compounds of general formula PSH.
  • R 3 is hydroxy or an amino acid chain comprising one or two amino acids and terminating in -C0 2 H and A and R 1 are as previously defined.
  • the compounds of general formula III are useful in preparing the compounds of general formula V.
  • the compounds of general formula III are suitably prepared by reacting a compound of general formula II
  • a - S - S - A or A - S - S - A' in which A' is different from A and is an aromatic activating residue.
  • reactants are either commercially available [e.g., 2,2'- dithiopyridine and 5,5'-dithiobis (2-nitrobenzoic acid)]or may be prepared by routine synthetic procedures well known to those skilled in the art.
  • a compound of general formula III for preparation of a compound of general formula III, in an exemplary procedure generally equal molar quantities of a compound of general formula II and a compound of formula A - S - S - A or A - S - S - A' may suitably be mixed in a polar organic solvent (e.g., ethanol) The product of general formula III may then suitably be isolated by crystallization from a nonpolar organic solvent (e g., benzene).
  • a polar organic solvent e.g., ethanol
  • a nonpolar organic solvent e.g., benzene
  • a fatty acid may for example be reacted with: (a) N-hydroxysuccinimide and a carbodiimide reagent to form an H-hydroxysucctnimidyl active ester; (b) tnfluoroacetic anhyd ⁇ de to form a fatty acid anhydride; or (c) thionyl chloride to form a fatty acid chlo ⁇ de
  • Alternative procedures may also suitably be employed to introduce these or other lipid- activating groups
  • hydrophobic substituent and "lipid- containmg moiety” refers to either a lipid group per se or a hydrocarbon-based group (in particular, one or more ammo acids) comprising a lipid group
  • Such hydrophobic substituents may comprise about 4 to about 26 carbon atoms, preferably about 5 to about 19 carbon atoms
  • Suitable hydrophobic groups together with the carbonyl to which they are attached in the formulae include, but are not limited to, fatty acid residues including mynstyl (C 13 H 27 ), palmityl (C 15 H 31 ), oleyl (C 15 H 29 ), stearyl (C 17 H 35 ), and elaidyl (C 17 H 33 ), as well as residues of ste ⁇ ods having carboxy groups including cholate, deoxycholate, 17-carboxyequ ⁇ len ⁇ n and 17-carboxyestrone
  • aromatic activating residue is meant a moiety which serves to make the disulfide group of the compounds of general formula V more labile to the displacement reaction with the sulfhydryl- containing compounds of general formula PSH (and thus, serves as a good leaving group)
  • aromatic activating group is 2-pyr ⁇ dyl, other suitable aromatic activating groups include 4-n ⁇ trophenyl
  • lipid-activating group refers for purposes of the present invention to a moiety which renders a carboxylipid group to which it is attached reactive with a compound of general formula III
  • a presently preferred lipid-activating group is N-hydroxysuccinimidyl ester, other suitable lipid-activating groups include acid chloride and acid anhyd ⁇ de
  • Biopolymers of interest include peptides, proteins, and oligonucleotides (as hereinafter defined)
  • biopolymers or thiolated biopolymers containing sulfhydryl groups may comprise a plurality of moieties corresponding in structure to the conjugates of general formula VI (i e , groups having the structure of the compounds of general formula VI minus the moiety P)
  • peptide refers to amino acid chains comprising two to 50 ammo acids and the term "protein” to amino acid chains comprising more than 50 am o acids
  • the proteins and peptides may be isolated from natural sources or prepared by means well known in the art, such as recombtnant DNA technology
  • the peptides and proteins used in accordance with the present invention may comprise only naturally-occurring L-amino acids, combinations of L-amino acids and other amino acids (including D-amino acids and modified amino acids), or only ammo acids other than L-amino acids
  • the peptide or protein must bear at least one reactive thiol group.
  • the peptide or protein contains cysteine residues (an amino acid comprising a thiol group)
  • cysteine residues an amino acid comprising a thiol group
  • a peptide or protein which does not contain a thiol group may be modified by procedures well known per se to those working in the field; in particular, well known thiolatmg agents [e g , N-succ ⁇ n ⁇ m ⁇ dyl-3-(2-pyridyldithio)prop ⁇ onate (SPDP) and 2- ⁇ m ⁇ noth ⁇ olane (Traut's reagent)] may be routinely employed for this purpose
  • oligonucleotide refers to chains comprising two or more naturally-occurring or modified nucleic acids, for example naturally-occurring or recombinant deoxy ⁇ bonucleic acids (DNA) and nbonucleic acid (RNA) sequences
  • the oligonucleotide must be modified by thiolatmg reactions so as to contain a sulfhydryl group for linking with the lipid-contaming moiety
  • modifications may be routinely carried out in a manner known per se
  • an oligonucleotide may be coupled to cystamine using carbodiimide and subsequently reduced by dithiothreitol to generate a free sulfhydryl group
  • Such oligonucleotide conjugates can be used to deliver therapeutically effective oligonucleotides in vivo or ex vivo, that is, the conjugate is contacted with the cells in vitro to effect transfection The cells may then be
  • Antisense oligonucleotides are DNA or RNA molecules or derivatives of a DNA or RNA molecules containing a nucleotide sequence which is complementary to that of a specific mRNA
  • An antisense oligonucleotide binds to the complementary sequence in a specific mRNA and inhibits translation of the mRNA
  • antisense oligonucleotides and derivatives thereof See, for example, U S Patent Nos 5,602,240, 5,596,091, 5,506,212, 5,521 ,302, 5,541,307, 5,510,476, 5,514,787, 5,543,507, 5,512,438, 5,510,239, 5,514,577, 5,519,134, 5,554,746, 5,276,019, 5,286,717.
  • WO96/35706, W096/32474, W096/29337 thiono t ⁇ ester modified antisense o godeoxynucleotide phosphorothioates
  • WO94/17093 oligonucleotide alkylphosphonates and alkylphosphothioat.es
  • WO94/08004 oligonucleotide phosphothioates, methyl phosphates, phosphoramidates, dithioates, bridged phosphorothioates, bridge phosphoramidates, sulfones, sulfates, ketos, phosphate esters and phosphorobutylamines (van der Krol ef al , Biotech 6958-976 (1988), Uhlmann et al , Chem Rev 90 542-585 (1990)), WO94/02499 (oligonucleotide alkylphosphonothioar.es and arylphospho
  • Preferred antisense oligonucleotides include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S- oligos, see, Jack Cohen, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press (1989)).
  • S-oligos are isoelectronic analogs of an oligonucleotide (O- oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom.
  • the S-oligos may be prepared by treatment of the corresponding O-oligos with 3H-1 ,2-benzodithiol-3-one- 1,1-dioxide which is a sulfur transfer reagent. See Iyer ef al., J. Org. Chem. 55:4693-4698 (1990); and lyer ef al., J. Am. Chem. Soc. 772:1253-1254 (1990).
  • R 1 is hydrogen, R 2 is a hydrophobic substituent or lipid moiety and R 3 is -OH.
  • This type of conjugate is suitably derived from cysteine.
  • R 1 is hydrogen, R 2 is -CH 2 CH 2 CH(NH 2 )C0 2 H or -CH 2 CH 2 CH(NHCO-lipid)CO-lipid and R 3 is -NHCH 2 C0 2 H or -NHCH 2 CO-lipid in which at least one of R 2 and R 3 together with the attached carbonyl is a lipid residue.
  • This type of conjugate is suitably derived from glutathione.
  • P 1 is a residue derived from a disulfide-containing compound which optionally may comprise a disulfide group linked to a hydrophobic group
  • P and (N) are preferably drugs
  • Conjugate (X) is preferably an organic compound n is an integer between 1 and 20, preferably no greater than 10, and more preferabaly no greater than 5
  • R 1 , R 2 and R 3 are as previously defined for Formula VI
  • R 4 is hydrogen, lower alkyl or aryl
  • R 5 is a hydrophobic substituent (as previously defined)
  • R 6 is hydroxy, a hydrophobic substituent or an ammo acid chain comprising one or two ammo acids and terminating in -C0 2 H or -COR 2
  • R 1 can be the same or different from R 4
  • R 2 can be the same or different from R 5
  • R 3 can be the same or different from R 6
  • R 2 and R s together with the attached carbonyl are each preferably (1) a lipid-containing moiety comprising a lipid group, or (2) a lipid-containing moiety comp ⁇ sing a lipid group with an am o acid chain comprising one or two am o acids and terminating in -C0 2 H
  • R 3 and R 6 are each preferably (1) an hydroxy group, (2) a hydrophilic group, or (3) an ammo acid
  • a non-limiting example of R 3 and R 6 is glycine
  • Non-limiting examples of R 2 and R 5 are glutamic acid derivative fatty acids and steroids such as deoxycholate and cholate
  • the invention disclosed herein can be applied to many biologically-active agents including, but not limited to, sulfhydryl- or disulfide-containing proteins and peptides Generally, these agents are poorly transported across biological barners, rapidly eliminated from plasma, and susceptable to chemical and proteolytic degradation, therefore, their therapeutic applications are limited
  • the invention disclosed herein can overcome part or all of these limitations
  • sulfhyryl- or disulfide-containing proteins and peptides include, but not limited to, insulin [Czech, M P , Ann Rev Biochem , 46, 359 (1977)], calcitonin [Brown, E M , Aurbach, G D , Vitam Horm , 38, 236 (1980)], desmopressin [Vavra et al , J Pharmacol Exp Ther , 188, 241(1974)], interferon-alpha, -beta, and -gamma [Stiem, E R , Ann Inter Med ,
  • Gly denotes glycme
  • Glu denotes glutamic acid "n 1 " is an even integer, preferably no greater than 10
  • group P 1 contains a sulfhydryl group, it is possible to link a further hydrophobic group via a disulfide bond according to the present invention to give conjugates having an odd number of hydrophobic substituents, e g where n 1 is an odd number
  • conjugates are particularly useful for increasing the absorption and prolonging blood and tissue retention of the disulfide-containing compounds
  • methods for increasing the absorption or prolonging blood and tissue retention in an animal such as a mammal of a conjugate (X) which is administered to the animal as part of a pharmaceutical composition (for example, in an aqueous solution or an oral dosage form)
  • Conjugate (X) is preferably formed from a compound containing one or more disulfide bonds and, optionally, one or more thiol groups
  • a disulfide-containing compound such as a peptide, protein, or compound (N) modified into a disulfide containing compound (such as compound (L) in Scheme IV)
  • conjugate (X) conjugate
  • the compound of Formula V is exemplified by compound (C) in Schemes II, III and IV
  • the appropriate compound with the general Formula V to produce a desired conjugate (X)
  • Conjugate (X) may be converted to the original disulfide molecules or compound (N) upon reaching blood or tissues
  • conjugate (X) overcome major limitations on peptide, polypetide, protein, and organic compound (N) drug formulations, by improving the in vivo permeability, stability, and bioavailability of the peptide, protein, and organic compound (N), which may serve as drugs
  • conjugate (X) e , fatty acid-peptide conjugates or fatty acid-drug conjugates
  • the invention has the following advantages over the prior art (1) the reaction can be carried out in aqueous conditions, (2) the products are generally water soluble, and (3) the product can be converted to the original peptide in the blood or tissues and thus a pharma
  • the methods may be used to prepare fatty-disulfide conjugates of cyclic disulfide-containing peptide drugs or homrones by using compound of the general Formula V (lipidizing agents).
  • lipidizing agents lipidizing agents
  • a cyclic disulfide bond in a peptide or polypeptide A
  • B two free sulfhydryl groups
  • These sulfhydryl groups can react with fatty acid-disulfide derivatives such as N-acylcysteine pyridine disulfide (C) to yield a di-fatty acid- disulfide conjugated peptide or polypeptide derivative of the general formula (D).
  • This derivative (D) can have an increased permeability to cells and a prolonged retention time in tissues. Preferably, it does not have any biological activity.
  • derivative (D) When the derivative (D) is administered into a patient's body and is reduced in vivo, derivative (D) can be converted to the original peptide or polypeptide (A).
  • Scheme III illustrates another embodiment of the above invention: the preparation of fatty acid derivatives from disulfide-crosslinked two-chain polypeptides to produce the conjugate of the general formula (H).
  • Conjugate (X) is desirable in that it is water soluble, it has lipophilic moiety or moieties which make it easier to be absorbed into a cell because it has cleavable linkage(s) which allow(s) for its sustained release in vivo
  • the peptide or polypeptide may have any number of amino acids and cyclic disulfide bonds. Modification of the peptide or protein typically takes place in aqueous solution such as PBS, or other buffers known in the art.
  • the fatty acid that may be used generally have between 4 to 26 carbons, and more generally between 5 to 19 carbons.
  • the non-limiting examples of the fatty acids are acetic acid (with 2 carbons); caproic acid (with 6 carbons); capric acid (with 10 carbons); lau ⁇ c acid (with 12 carbons); myristic acid (with 14 carbons); palmitic acid (with 16 carbons); and stearic acid (with 18 carbons) (See .Example 11, below).
  • the method of Scheme II is generally useful for a peptide or polypeptide having between one to five cyclic disulfide bonds.
  • the reaction may be carried out at room temperature.
  • the fatty acid is generally at an excess in molar concentration over the peptide or polypeptide; generally the ratio between the fatty acid and peptide or polypeptide for one cyclodisulfide is 3 to 1.
  • conjugate (X) the fatty acid is generally less than the peptide or polypeptide by weight
  • the relatively small amount of the fatty acid poses less toxic concern, unlike the administration of drug in lipid formulation, micelles, or liposomes
  • Conjugate (X) may be purified using methods known in the art for purifying proteins and peptides The peptide or polypeptide in the conjugate confirmed by methods known in the art, such as by chromatography
  • Examples of the peptides or proteins that can be modified according to Scheme II are desmopressin (a nanopeptide with 9 ammo acids and one cyclic disulfide ring, see Example 11 , below), cal ⁇ tonin (a peptide with 30 ammo acids and one cyclic disulfide ring, see Example 17, below), octreotide (an octapeptide with one cyclic disulfide ring), oxytocin (a nanopeptide with one cyclic disulfide ring); and epidermal growth factor (a single polypeptide chain consisting of 53 ammo acids with three cyclic disulfide rings) Insulin is an example of a polypeptide that can be modified according to Scheme II or III, since the insulin polypeptide consists of two chains (A- and B- chains) and a total of 51 ammo acids with one cyclic disulfide ring in the A-chain (available for modification according to Scheme II) and one ring structure formed by two dis
  • the fatty acids moiety of conjugate (X) may be substituted with other lipids, such as steroids (examples of which are shown in Examples 15 and 16, below)
  • a good leaving group is defined as a moiety which serves to make the disulfide group of the compound (A) of general formula V more labile to displacement reaction with sulfhydryl-containing compounds of general formula PSH, and thus serving as a good leaving group
  • Non-limiting examples of good leaving groups are p-nitro-o-carboxyl-thiophenol and thiopyndine
  • the definition of a leaving group can be found in most organic chemistry textbooks. For example, in page 241 of Cram and Hammond's Organic Chemistry, McGraw-Hill Book Co.
  • a leaving group "L” is defined as that "the C-L bond is ruptured in such a way that the pair of electrons which compose the bond becomes associated with L.” Therefore, a moiety in an organic molecule is a good leaving group if it is capable of withdrawing the pair of electrons by either a high electronegativity or a resonance stability.
  • the fatty acid conjugates of the present invention are soluble in most buffer solutions in which proteins and peptides are soluble.
  • any free carboxylic acid groups are charged at neutral pH and therefore improve the solubility of the conjugates. This greatly facilitates the formulation of the conjugates with suitable pharmaceutically-acceptable carriers or adjuvants for administration of the proteins or peptides to a patient by oral or other routes.
  • conjugate (X) may be made by conjugating a compound of the general formula VI 1 with a compound of the general formula VI 2 to form the compound of general formula (X).
  • General formulae VI 1 and VI 2 are shown below:
  • P 2 and P 3 are residues derived from sulfhydryl-containing compounds, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as previously described. It will be clear to one skilled in the art that compounds of general formulae VI 1 and VI 2 are examples of the compound with the general formula VI, described previously. Upon conjugation, P 2 and P 3 become P 1 .
  • P 1 , P 2 and P 3 are proteins or peptides, thus one skilled in the art may perform the synthesis by modifying peptide or protein conjugation methods known in the art.
  • the disulfide linkage between the fatty acid moiety and the peptide or protein may readily be reduced. Therefore, the active peptide or protein molecules are released in intact form inside the target tissues or cells. Furthermore, the fatty acid moiety of the conjugates comprises only amino acids and lipid molecules which are not toxic to mammals, in particular humans.
  • compositions of the present invention may be administered by any means that achieve their intended purpose.
  • administration may be by oral, parenteral, subcutaneous, intravenous, intramuscular, intra-peritoneal, transdermal, intrathecal or intracranial routes.
  • the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • compositions within the scope of this invention include all compositions wherein the compounds of the invention are contained in an amount effective to achieve their intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each compound is within the skill of the art.
  • the compounds may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
  • suitable formulations for parenteral administration include aqueous solutions of the compounds in water- soluble form.
  • suspensions of the compounds as appropriate oily injection suspensions may be administered.
  • Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may also contain stabilizers.
  • the compounds of the invention may also be combined with a lipophilic cationic compound which may be in the form of liposomes.
  • a lipophilic cationic compound which may be in the form of liposomes.
  • the use of liposomes to introduce nucleotides into cells is taught, for example, in U.S. Patent Nos. 4,897,355, 4,394,448 and 5,635,380. See also U.S. Patent Nos. 4,235,871, 4,231,877, 4,224,179, 4,753,788, 4,673,567, 4,247,411 , 4,814,270 for general methods of preparing liposomes comprising biological materials.
  • a metholic solution of dimyristoyl phosphatidyl choline, cholesterol and stearylamine (7:2:1 ) are evaporated to obtain a dry film.
  • the film is hydrated in Tris® buffer containing appropriate amount of lipidized compound, followed by probe sonication.
  • Pal-PDC (V) was separated from palmitic acid by suspension of the precipitate in water, pH 7.0, which dissolved Pal-PDC (V), but not palmitic acid. Pal-PDC (V) was purified further using two more steps of acid precipitation as described above.
  • BBI conjugates of BBI were synthesized.
  • BBI is a hydrophilic protein which has low uptake into cells and is not orally bioavailable.
  • BBI is stable in the Gl tract and resists degradation by the mammalian proteases in the gut [Yaveiow, J., et al., Cancer. Res , 43:2454s-2459s (1983)].
  • the use of BBI for chemoprevention can be accepted only if an orally absorbable form of BBI can be developed.
  • BBI (20 mg) was dissolved in 1 ml of a sodium bicarbonate solution (0.3 M, pH 8.0) and reacted with SPDP (5 mg/100 ⁇ l of DMF) for 2 hr at 25°C.
  • SPDP 5 mg/100 ⁇ l of DMF
  • the PDP-derivatization of BBI was estimated by measuring the release of the thiopyridine moiety after reduction of BBI-PDP with dithiothreitol (DTT). Using this procedure, approximately 4 amino groups per BBI molecule were modified with SPDP.
  • the level of derivatization of BBI could be controlled by adjusting the pH of the reaction buffer; the modification of BBI could be adjusted from one amine group per BBI molecule when the reaction was carried out at pH 7, to 4.5 amine groups modified when the reaction was carried out at pH 8.5.
  • BBI-PDP (20 mg) in PBS (1 ml, pH 5.0) was reduced with DTT (25 mM) for 30 min and subsequently eluted from a Sephadex® G50 column.
  • the reaction mixture was then acidified to pH 3.0 using HCI (1M) and left on ice for 30 min.
  • the supernatant was analyzed separately using a Sephadex® G25 gel-filtration column.
  • the precipitate which contained the palmityl disulfide conjugate of BBI, BBIssPal (VI), and the excess reagent, was isolated by centrifugation, dissolved in DMF (2 ml), and eluted from a Sephadex® LH20 column using DMF.
  • BBIssPal (VI) fractions which eluted at column void volume, were isolated, dialyzed 3 times against 500 volumes of water, and then lyophiiized. The yield of the conjugate using this procedure was approximately 80% (by weight).
  • the conjugation of Pal-PDC to BBI was confirmed and quantitated after the conjugation of [3H]-labeled Pal-PDC (V) to BBI using identical conjugation conditions as the ones described above. Also, using an identical procedure, the oleic acid conjugated BBI (BBIssOleic) was synthesized.
  • Human colon carcinoma cells (Caco-2) were detached from 25 cm 2 stock culture flasks using a 10 min incubation at 37°C with 0.5 ml of a trypsin/EDTA solution (0.5% trypsin, 5.3mM EDTA). The cells were then suspended in 5 ml of Dulbecco's minimum essential medium, supplemented with 15% fetal bovine serum (FBS), L-glutamine (1%), and essential amino acids (1%), and counted using a coulter counter.
  • FBS fetal bovine serum
  • L-glutamine 1%
  • essential amino acids 1%
  • Radioiodination of BBI and BBIssPal was carried out using the chloramine-T method [McConahey, P.C. and Dixon, F.J., Meth. Enzymol., 70:221-247 (1980)].
  • Confluent, 14-day old cell monolayers were washed once with, and then incubated in, serum-free Dulbecco medium at 37°C for 30 min. Subsequently, the incubation medium was replaced with serum free medium containing 125 l- BBI (10 ⁇ g/ml), either as native-BBi or as BBIssPal or BBIssOleic, and the monolayers were incubated for a further 60 min at 37°C.
  • the monolayers were then washed three times with ice-cold PBS, and then exposed to trypsin (0.5%, EDTA 5.3mM) for 10 min at 37°C.
  • the detached cells were transferred to tubes, isolated by centrifugation, washed three times using ice-cold PBS, assayed for accumulated radioactivity using a gamma counter, and finally assayed for cell protein using the published method [Lowry, O.H., et al., J. Biol. Chem., 193:265-275 (1951)].
  • 125 l-BBIssPal In some experiments the uptake of reduced 125 l-BBIssPal into cells was determined. 125 l- BBIssPal was reduced with DTT (50 mM) at 60°C for 5 min followed by a further 25 min at 37°C. In control experiments, 125 l-BBIssPal was exposed in medium to the same temperatures without being exposed to DTT.
  • the uptake of 125 l-BBIssPal in the presence of BSA (fatty acid free) was determined as follows. 125 l-BBIssPal was incubated with medium containing 0.1% BSA for 30 min at 37°C before being added to the cell monolayers. In some uptake experiments, BSA was first mixed with a 3- fold molar excess of palmitic acid, and then incubated with the conjugates prior to the experiments. In the experiments where the uptake of 125 l-BBIssPal was determined in medium containing FBS, the conjugates was simply added to the medium containing the required amount of FBS.
  • Confluent cell monolayers 2 to 3 weeks old, and having a TEER value of approximately 500 ⁇ cm 2 , were first incubated with Dulbecco's MEM containing 1 % of FBS for 30 min at 37°C. Subsequently, the incubation medium was removed, and the 125 I-BBI (10 ⁇ g/ml) conjugates in 1.5 ml of the medium was added to the apical chamber of the transwells. To the basal chamber, 2.5 ml of the medium was added and the transwells were incubated at 37°C. At predetermined times, the entire basal chamber medium (2,5 ml) from each transwell was removed and counted for radioactivity using a gamma counter.
  • the cell monolayers were incubated with 125 l-labeled conjugates at 10 ⁇ g/ml for 60 min at 37°C.
  • the results presented are the average of three monolayers ⁇ SEM.
  • the uptake experiments were carried out in Dulbecco medium, in the presence and absence of added FBS.
  • the cell uptake of 125 I-BBI, either as the native protein or as BBIssPal was determined before and after reduction with DTT (50 mM) for 5 min at 60°C and 25 min at 37°C.
  • Bovine serum albumin (BSA) is known to be a carrier of fatty acids in vivo and contain hydrophobic regions which can tightly bind fatty acids. Since the uptake of 25 l-BBIssPal was reduced in the presence of serum, the possibility that BBIssPal bound to BSA present in FBS was investigated. The cell uptake of 125 l-BBIssPal and 1 5 I-BBI in the presence of medium containing fat-free BSA or fatty acid-loaded BSA was studied, and the results are shown in Table 3. In the presence of BSA-free medium, the uptake of 125 l-BBIssPal into the cells was 80-fold higher than that of BBI, as was expected from the results obtained in the previous experiments.
  • the uptake experiments were carried out in Dulbecco medium, in the presence and absence of added fatty acid-free BSA (BSA) or fatty acid-loaded BSA (BSA/FA).
  • BSA fatty acid-free BSA
  • BSA/FA fatty acid-loaded BSA
  • the results of studies of the uptake of 125 I-BBI, either as the native-BBI or in conjugated form to palmitic or oleic acid, in Caco-2 cells in the presence of serum-free medium are presented in Fig. 1.
  • the uptake of 5 l-BBIssPal into the cells was approximately 100-fold higher than that of 125 I-BBI.
  • the uptake of 12S l-BBIssOleic into the cells was about 108-fold higher than 125 BBI.
  • the difference between the uptake of 125 l-BBIssPal and 125 l-BBIssOleic were not significant.
  • mice Female CF-1 mice, 2 to 3 weeks old, weighing 20-25 g each, with free access to food and water prior to the experiments, were used for the animal experiments.
  • 3 animals from each experiment group were sacrificed and their blood (200 ⁇ l), the kidneys, the lungs, and the liver were removed, rinsed in ice-cold PBS, and assayed for accumulated radioactivity. The weights of the organs were recorded and used to adjust the concentration of the conjugates in the organs.
  • I-BBI 1 5 I-BBI (3 mg/kg), either as the native-BBI or as BBIssPal, was administered into the lower left quadrant of the abdominal cavity of each animal. The animals were then treated in the manner described for the iv.-biodistribution studies.
  • Fig. 2 The results of the biodistribution of BBI and BBIssPal following iv-administration are shown in Fig. 2 as the % dose accumulated per g organ ⁇ SEM.
  • the liver accumulation of BBIssPal was approximately 5-fold higher than that of BBI, and BBIssPal levels remained high in the liver even at 24 hr post-injection.
  • BBIssPal The lung accumulation of BBIssPal was also approximately 2-fold higher than that of BBI, but this result may have been caused by the residual blood present in the organ after its excision. Clearly, BBIssPal was retained longer and at a higher level in the blood and the liver. On the other hand, the kidney clearance of BBIssPal was about 4-fold lower than native-BBI.
  • the biodistribution of BBIssOleic was very similar to BBIssPal. As was observed for BBIssPal, BBIssOleic had higher blood levels than BBI and was apparently more slowly cleared from the circulation. The blood levels of BBIssOleic were about 4-fold higher than those of BBI at the same time points. The kidney clearance of BBIssOleic was approximately 4-fold lower, and the liver accumulation approximately 4-fold higher than native-BBI.
  • BBIssOleic in the liver was prolonged, with significant levels of the conjugate present in the liver even at 24 hr post-injection.
  • the lung levels of BBIssOleic were about 2-fold higher than native-BBI levels, but the higher residual blood in the lungs could account for this observation.
  • Fig. 4 The iv-biodistribution of 125 l-BBIssPal in CF-1 mice is shown in Fig. 4 as the average % dose accumulation per organ " range (bars) at 0.5 hr (Fig. 4A), 3 hr (Fig. 4B) or 24 hr post-injection (Fig. 4C).
  • the kidney accumulation of 125 l-BBIssPal was 4-fold lower than that of native 125 I-BBI for the 0.5 and 3 hr time points.
  • 1Z5 l-BBIssPal levels were higher in the kidneys than 125 I-BBI.
  • the blood level of 125 l-BBIssPal was similar to that of 12S I-BBI at 0.5 hr, 1.5-fold higher than BBI at 3 hr, and approximately 3-fold higher than BBI at 24 hr.
  • the liver accumulation of 125 l-BBIssPal was 1.5-fold higher than 125 I-BBI at 0.5 hr, 2.5-fold higher at 3 hr, and about 4-fold higher at 24 hr. Relatively large amounts of 25 l-BBIssPal were present in the liver and the kidneys at 24 hr.
  • Transformation assays were carried out using C3H 10T1/2(clone 8) cells according to the published recommendations [Reznikoff, C.A., etal., Cancer. Res., 33:3239-3249 (1973); Reznikoff, C.A., et al., Cancer. Res., 33:3231-3238 (1973)].
  • Stock cultures of mycoplasma-free cells were maintained by passing 50,000 cells per 75 cm 2 flask every seven days. Using this schedule, the cells were always passed approximately 2 days before reaching confluence.
  • the stock culture was grown in Eagle's basal medium supplemented with 10% FBS, penicillin (100 units), and streptomycin (100 ⁇ g) and used for the transformation assays at passages of 9 to 14.
  • the cells were passed by treating the stock cells with trypsin (0.1%) in PBS for 5 min and quenching the trypsin with 5 ml of the medium. This procedure was adapted to minimize spontaneous transformation in the stock cultures and maximize the plating efficiency in the petri dishes.
  • the FBS stock used in the cultures was pre- screened to ensure that the serum was able to support the expression and the growth of the transformed cells.
  • C3H 10T1/2 cells 1000/dish were seeded into 60 mm petri dishes and allowed to grow in a humidified 5% C0 2 atmosphere in Eagle's basal medium, supplemented with 10% FBS, penicillin (100 units), and streptomycin (100 ⁇ g), for 24 hr. Subsequently, the cells were initiated by treatment with 25 ⁇ l of the 3-methylcholanthrene (MCA) in acetone stock solution (0.25 mg/ml) to a final concentration of 1 ⁇ g/ml of MCA (5 ⁇ g/5 ml).
  • MCA 3-methylcholanthrene
  • the cells were allowed to grow in the presence of the carcinogen or solvent for 24 hr, and the medium in each dish was then replaced with fresh medium containing no carcinogen or solvent.
  • the medium in the dishes was replaced twice per week for the first two weeks of the assay, and thereafter once a week for the remainder four weeks of the assay.
  • the cells were maintained in the medium containing the conjugates (1 ⁇ g/ml) for the first three weeks of the assay; thereafter, the cells were maintained in medium containing no added conjugates.
  • the cells were inspected under a microscope for adherence to the culture dishes and were washed with PBS and then fixed in 100% methanol. The fixed monolayers were then stained with Giemsa stain. Twenty dishes per group were treated in each experiment.
  • all the transformation assays contained at least three other groups: negative control (not treated with carcinogen or solvent), acetone control (treated with 25 ⁇ l of acetone), and positive control [treated with MCA (1 ⁇ g/ml) in 25 ⁇ l of acetone].
  • Type III foci were dense, multilayered, basophilic, areas of cell growth which stained to a deep blue color with Giemsa and had rough criss-crossed edges.
  • Type II foci were also dense, multilayered, areas of cell growth, but were stained to a purple color with Giemsa and had smoother, more defined edges compared to Type III foci.
  • Type I foci were not scored in the assay.
  • the plating efficiency (PE) of the cells was also studied in conjunction with each of the transformation assays.
  • cells 200 cells/dish
  • the cells in these assays were terminated at 10 days, fixed with 100% methanol, and stained with giemsa; the colonies of 50 cells or more visible under a microscope were then counted.
  • the plating efficiency is defined as the (number of colonies/number of cells seeded) x 100%.
  • BBI in vitro anti-transformation activity of BBI, BBIssPal, and BBIssOleic is shown in Table 4.
  • BBI either as the free protein or in conjugated form to palmitic or oleic acid, was added to the cultures at 1.0 ⁇ g/ml for the first three weeks of the transformation assay period starting immediately after the MCA treatment.
  • MCA-treated cells were exposed to 3-methylcholanthrene, dissolved in 25 ⁇ l of acetone, at a concentration of 1 ⁇ g/ml for 24 hr.
  • Acetone-treated cells were exposed to 25 ⁇ l of acetone for 24 hr only.
  • the test groups were exposed to MCA for 24 hr and then to the conjugates for the first three weeks of the assay.
  • Untreated cells were exposed to neither MCA nor acetone.
  • Statistical analysis (Chi-square): Group 4 vs 3, p ⁇ 0.05; Group 5 vs 3, 0.05 ⁇ p ⁇ 0.1; Group 6 vs 3, p ⁇ 0.05.
  • Control untreated cells reached confluence in the dishes about 14-days post-seeding formed well adherent, contact-inhibited monolayers. These dishes contained no transformed foci at the end of the assay period.
  • the acetone treated cells also reached confluence and formed well-adherent monolayers 14 days post-seeding and contained no transformed foci.
  • the MCA-treated dishes however, contained morphologically transformed foci: 6 out of the 19 dishes scored contained type III foci.
  • the BBI-treated group contained no transformed foci, indicating that BBI could prevent MCA- induced transformation in these cells.
  • the BBIssPal-treated cells contained one type II focus out of the 20 dishes scored in the assay.
  • the BBIssOleic treated cells contained no transformed foci.
  • the PE of all the groups in this assay was between 20% to 25%. As demonstrated in Table 4, both BBIssPal and BBIssOleic retained the original biological activity of BBI.
  • 125 I-BBI or 125 l-BBIssPal (10 ⁇ g/ml) was incubated with Caco-2 cells in serum-free medium for 1 hr at 37°C. Subsequently, the cells were rinsed three times with ice-cold PBS and then divided into two groups. In the first group the internalization of the conjugates was determined after the trypsinization and isolation of the cells.
  • the cells were reincubated with serum-free medium and the release of the conjugates from the cells was chased for 24 hr; medium was removed at hourly intervals and counted for radioactivity. At the end of the chase period, the cells were trypsinized, isolated, and counted for accumulated radioactivity. The total counts in each experiments (medium + cell cpms) were determined, and the % of the total counts released at different times was determined.
  • the conjugates were incubated with the apical side of the cells for 1 hr at 37°C.
  • the transwells were then rinsed three times with ice-cold PBS and then reincubated with serum free medium.
  • the release of the conjugates into the apical and the basal medium was chased for 24 hr by counting the entire basal or the apical medium at different times.
  • the total counts obtained at the end of the chase period (transwells + media counts were added, and the release of the conjugates (% of total) at different times was calculated.
  • the transwells were exposed to trypsin for 10 min, rinsed three times with ice-cold pbs, and subsequently counted for accumulated radioactivity.
  • BBI was modified with 2 or 4 palmitic acids, and the transport was determined in transwells.
  • the order of the transport extent was BBIssPal(4)>BBI>BBIssPal(2).
  • the results of the internalization of the conjugates into the same cells is shown in Fig. 5B as the ng of BBI internalized per monolayer.
  • BBIssPal(4) had the highest uptake into the cells, followed by BBIssPal(2) and BBI.
  • the basal media obtained at 24 hr from the transwells was analyzed using a G50 column; the results are shown in Fig. 6.
  • BBI nor BBIssPal(4) was transcytosed across the monolayers.
  • a small, but significant, amount of the basal media of BBIssPal(2) consisted of intact conjugate. This quantity consisted of between about 10 and about 20% of the total radioactivity present in the basal medium.
  • Freshly-prepared skins from hairless mice were mounted on small rings. To each mounted skin, a 5 ⁇ l sample of 125 l-labeled BBI or BBIssPal at a concentration of 0.5 mg/ml was applied to an area of 0.38 cm 2 . Two pieces of skin were used per treatment The skins were kept at room temperature (23°C) in a humidified environment. After 30 minutes, the surface of the skins was first ⁇ nsed carefully with PBS; subsequently, the skins were unmounted and soaked twice in 100 ml of PBS. The skins were then blotted with filter papers and counted in a gamma counter.
  • the amount of BBI retained on the skins was calculated using the specific radioactivity of the labeled BBI or BBIssPal.
  • the absorption of BBI and BBIssPal into the mouse skins was 0.14 and 1.6 ⁇ g/cm 2 , respectively. This demonstrates that a more than 10-fold increase of BBI absorption into the skin was achieved when the polypeptide was modified using Pal-PDC.
  • An antisense 21mer oligonucleotide which is complementary to the mRNA of monoamine oxidase B is thiolated using the following procedure.
  • the oligonucleotide is mixed with a two-fold molar excess of cystamine in the presence of a water-soluble carbodiimide reagent, EDC.
  • EDC water-soluble carbodiimide reagent
  • the mixture is maintained at 25 C C for 2 hours and a two-fold molar excess to cystamine of DTT is added to reduce disulfide bonds.
  • a small amount of the thiolated oligonucleotide is reacted with Ellman's reagent and the concentration of sulfhydryl groups determined using the absorbance at 412 nm (assuming an e of 1.36 x 10 4 M "1 ). Subsequently, the number of sulfhydryl groups per oligonucleotide molecule is determined.
  • the thiolated oligonucleotide is mixed in bicarbonate buffer, pH 8, with Pal- PDC in two-fold molar excess to the number of sulfhydryl groups in the oligonucleotide.
  • the palmitylated oligonucleotide is purified using a Sephadex® G-25 column.
  • the reduced DP solution was mixed with 2.24 ml of 10 mM Pal-PDC (10 mM, pH 7.6) for 30 min at 25°C and, subsequently, acidified to pH 3 using HCI (1 ).
  • the precipitate formed in the acidified reaction mixture which consisted of the palmityl disulfide conjugate of desmopressin (DP-P) and the excess reagent, was isolated by using centrifugation and re-dissolved in 1 ml of dimethylformamide (DMF).
  • DMF dimethylformamide
  • DP-P was subsequently purified by using a Sephadex® G 15 column (40 ml) using DMF as the eluant.
  • Brattleboro rats which carry the hereditary disease of hypothalamic diabetes insipidus, were used to compare the effects of DP and DP-P for alleviating the disease symptoms, i.e., polyuria and polydipsia.
  • a group of three Brattleboro rats were kept separately in three metabolic cages. Their body weight, water intake and urine output were measured every day.
  • DP and DP-P were dissolved in 10% Liposyn® II (Abbott Laboratories, Abbott Park, IL, USA) and injected subcutaneously (s.c.) to each rat at doses ranging from 0.02 to 20 ⁇ g/kg.
  • Liposyn® II Abbott Laboratories, Abbott Park, IL, USA
  • DP-P was at least 250-fold more effective than DP when administered subcutaneously for the treatment of diabetes insipidus, because a similar effect was obtained with 0.02 ⁇ g/kg of DP-P and 5 ⁇ g/ml of DP.
  • DP as well as its fatty acid derivatives, was tested for the anti-diuretic effects in Brattleboro rats.
  • Three rats were injected s.c. with DP or its fatty acid conjugates at a dose of 0.5 ⁇ g/kg in 10% Liposyn® II (Abbott Laboratories).
  • the urine output from each rat was measured, averaged, and plotted versus the number of days.
  • a minimum of 10 carbons is required for the fatty acid moiety in the DP-conjugates in order to increase the efficacy of the anti-diuretic activity.
  • Both DP and DP-P were iodinated with 125 l by using the chloramine T method.
  • 125 I-DP or 125 l- DP-P was injected intravenously to CF mice at a dose of 1x10 6 cpm/mouse.
  • Groups of three treated mice were sacrificed at different time points and the radioactivity in the blood was measured by counting 0.2 ml of blood in a gamma counter.
  • the plasma half-life of DP-P is much longer than that of DP, resulting approximately a 6-fold increase in AUC.
  • DP-DOC was prepared by a similar procedure as described in Example 11. Briefly 280 ⁇ l of 10 mM DOC-PDC (10 mM, pH 7.7) was added to a solution of the reduced DP (0.5 ml of 1 mg/ml PBS). The mixture was stirred at 25°C for 30 min when TLC analysis indicated that the conjugation reaction was completed. The reaction mixture was then acidified to pH 3 using HCI (1N) and the final product, DP-DOC, was isolated as the precipitate.
  • Salmon calcitonin (CT, 4 mg) was dissolved in 2 ml of PBS (pH 7.4) and treated with 46.6 ⁇ l of dithiothreitol (DTT, 0.1 M) at 37 C C for 30 min. The reduced calcitonin (dithiocalcitonin) was proceeded as such without isolation for the subsequent conjugation.
  • To the reaction mixture was added 1.4 ml of 10 mM Pal-PDC (10 mM, pH 7.6). The mixture was stirred at 25°C for 45 min and, subsequently, acidified to pH 3 using HCI (1N).
  • CT-P palmityl disulfide conjugate of conjugate of calcitonin
  • the precipitate was dissolved in 1 ml of DMF.
  • CT-P was purified by eluting in a Sephadex® LH20 column (40 ml) using DMF as the eluant.
  • Both CT and CT-P were iodinated with 125 l using chloramine T method.
  • 1 5 I-CT or 125 I-CT-P was injected s.c. into mice at a dose of 125 ⁇ g/kg in 10% Liposyn® II (Abbott). Groups of three mice were sacrificed at different time points.
  • the levels of calcium in the blood samples were determined by using a commercial calcium diagnostic kit (Sigma Chemical Co.).
  • the plasma from each mouse was isolated and treated with 5% trichloroacetic acid (TCA) in an ice bath. The radioactivity in the TCA precipitates were considered as the intact CT in the plasma.
  • TCA trichloroacetic acid
  • CT-P-injected mice showed a transient reduction of the plasma calcium level, indicating that CT-P retains the in vivo biological activity of CP. More importantly, s.c. injected CT-P, in contrast to the rapid plasma clearance of s.c. injected CT, maintained an almost constant level of CT or CT-P in the blood for approximately 16 hours.
  • C-P Gastro-intestinal absorption and calcium-lowering effect of orally administrated calcitonin-palmitic acid coniugate
  • CT and CT-P were orally administered to CF mice using a gavaging needle at a dose of 100 ⁇ g/kg in PBS.
  • the levels of CT and calcium were measured by using commercial CT-RIA (Phoenix) and calcium diagnostic (Sigma Chemical Co.) kits, respectively. The results are shown in Table 5.
  • the level of RIA-detected CT in mice with oral administration of CT-P was significantly higher than that of CT.
  • the level of calcium in plasma at 1 hour was lower in CT-P treated mice than that in CT treated mice, which was consistent with the finding in CT levels.
  • ACV-LA acyclovir
  • LA lipoic acid
  • TsOH p-toluenesulfonic acid
  • Acyclovir (ACV, 25 mg), lipoic acid (LA, 229 mg), and dicyclohexylcarbodiimide (572.5 mg) were dissolved together in DMF (2.5 ml). To the resultant solution was added 10.8 mg of TsOH. The mixture was stirred at room temperature for 3 days. The dicyclohexylurea precipitate was removed by filtration. DMF in the filtrate was evaporated under vacuum. The residue from evaporation was suspended in 5 ml of deionized water and extracted with ethyl ether (2 x 3 ml). The aqueous layer was separated and lyophilized.
  • the lyophilized residue was redissolved in a small volume of methanol and loaded onto a preparative TLC plate.
  • the plate was developed using methylene chloride:acetone:methanol (4:1:1) as the solvent system.
  • the solvent extract was evaporated in a rotary evaporator and a final product of 11.7 mg of ACV-LA was obtained.
  • Acyclovir-lipoic acid ester (ACV-LA, 0.6 mg) was dissolved in 0.5 ml of PBS (pH 7.4) and treated with 14.5 ml of dithiothreitol (DTT, 0.1 M). The reduction was proceeded at 37°C for 30 min. The reduced ACV-LA (dithiol compound) was used without further purification for the subsequent conjugation.
  • To the reaction mixture was added 531 ⁇ l of 10 mM Pal- PDC (10 mM, pH 7.7). The mixture was stirred at 25°C for 30 min. The reaction mixture was acidified to pH 3 using HCI (1N) and precipitation appeared. The precipitate, which contained ACV-LA-DP, was obtained. The product could be further purified by chromatographic methods.
  • Liposomal DP-P as well as DP-P in Tris ® buffer, was tested for its anti-diuretic effects at an oral dose of 37.5 ⁇ g/kg in Brattleboro rats.
  • a metholic solution of dimyristoyl phosphatidyl choline, cholesterol and stearylamine (7:2:1) was evaporated to obtain a dry film.
  • the film was hydrated in Tris ® buffer (2 ml) containing appropriate amount of DP-P (2 hrs/25°C), followed by probe sonication (15 min/37°C).
  • the resultant liposomal preparation was diluted with Tris ® buffer to a total volume of 5 ml, which was used immediately.

Abstract

Cette invention se rapporte à des dérivés acides gras de composés contenant du disulfure (par exemple des peptides ou des protéines contenant du disulfure), qui comprennent des produits modifiés par conjugaison avec des acides gras, présentant une liaison disulfure, ces dérivés étant utilisés pour administrer les composés à teneur en disulfure dans des cellules de mammifères. La modification ainsi apportée augmente considérablement l'absorption desdits composés par les cellules de mammifères par rapport à la vitesse d'absorption de tels composés non conjugués, et elle prolonge la rétention de ces composés dans le sang et les tissus. En outre, la liaison disulfure du conjugué est très labile in vivo et elle facilite par conséquent la libération intracellulaire ou extracellulaire des composés intacts à partir des fractions d'acides gras.
PCT/US1997/017282 1996-09-26 1997-09-26 Procedes et compositions pour la lipidation de molecules hydrophile WO1998013007A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP97944483A EP1023316A4 (fr) 1996-09-26 1997-09-26 Procedes et compositions pour la lipidation de molecules hydrophile
BR9712128-2A BR9712128A (pt) 1996-09-26 1997-09-26 Métodos e composições para lipidização de moléculas hidrofìlicas
CA002267179A CA2267179A1 (fr) 1996-09-26 1997-09-26 Procedes et compositions pour la lipidation de molecules hydrophile
AU45967/97A AU737865B2 (en) 1996-09-26 1997-09-26 Methods and compositions for lipidization of hydrophilic molecules
JP51593398A JP2002515883A (ja) 1996-09-26 1997-09-26 親水性分子の脂質化のための方法および組成物
IL12917797A IL129177A0 (en) 1996-09-26 1997-09-26 Methods and compositions for lipidization of hydrophilic molecules
NO991465A NO991465L (no) 1996-09-26 1999-03-25 FremgangsmÕter og preparater for lipidisering av hydrofile molekyler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72130696A 1996-09-26 1996-09-26
US08/721,306 1996-09-26
US4949997P 1997-06-13 1997-06-13
US60/049,499 1997-06-13

Publications (3)

Publication Number Publication Date
WO1998013007A2 true WO1998013007A2 (fr) 1998-04-02
WO1998013007A9 WO1998013007A9 (fr) 1998-08-13
WO1998013007A8 WO1998013007A8 (fr) 1999-05-20

Family

ID=26727231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/017282 WO1998013007A2 (fr) 1996-09-26 1997-09-26 Procedes et compositions pour la lipidation de molecules hydrophile

Country Status (10)

Country Link
EP (1) EP1023316A4 (fr)
JP (1) JP2002515883A (fr)
KR (1) KR100691315B1 (fr)
CN (1) CN1127477C (fr)
AU (1) AU737865B2 (fr)
BR (1) BR9712128A (fr)
CA (1) CA2267179A1 (fr)
IL (1) IL129177A0 (fr)
NO (1) NO991465L (fr)
WO (1) WO1998013007A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058152A1 (fr) * 1998-05-12 1999-11-18 University Of Florida Lipides cationiques a liaisons disulfure pour l'administration intracellulaire de substances therapeutiques
WO2002066067A2 (fr) * 2001-02-16 2002-08-29 King's College London Nouveau systeme d'administration de medicaments
JP2002531543A (ja) * 1998-12-10 2002-09-24 ユニバーシティ・オブ・サザン・カリフォルニア 可逆性水性ｐＨ感受性脂質化剤、組成物および使用方法
EP1663933A2 (fr) * 2003-09-08 2006-06-07 Mirus Bio Corporation Transfert ameliore de medicaments par des modifications hydrophobes instables
WO2008057298A3 (fr) * 2006-10-27 2008-07-03 Wei-Chiang Shen Interféron lipidisé et ses utilisations
US20090239790A1 (en) * 2003-12-31 2009-09-24 Chadler Pool Novel recombinant proteins with n-terminal free thiol
US20160009643A1 (en) * 2013-02-28 2016-01-14 Qiaobing Xu Disulfide compounds for delivery of pharmaceutical agents
US20160082126A1 (en) * 2013-05-13 2016-03-24 Tufts University Nanocomplexes for delivery of saporin

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134352A4 (fr) * 2007-03-05 2011-05-25 Univ Leland Stanford Junior Compositions de wnt et procédés pour leur utilisation
EP2247613B1 (fr) * 2008-02-21 2018-05-30 Dermacare Neuroscience Institute Formulations cosmétiques et dermatologiques de peptides mntf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
CA2260761C (fr) * 1996-06-25 2011-05-03 Nico Johannes Christiaan Maria Beekman Vaccins comprenant des antigenes fixes sur leurs supports par des liaisons labiles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1023316A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153434A (en) * 1998-05-12 2000-11-28 University Of Florida Methods for the intracellular delivery of substances
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
WO1999058152A1 (fr) * 1998-05-12 1999-11-18 University Of Florida Lipides cationiques a liaisons disulfure pour l'administration intracellulaire de substances therapeutiques
JP2002531543A (ja) * 1998-12-10 2002-09-24 ユニバーシティ・オブ・サザン・カリフォルニア 可逆性水性ｐＨ感受性脂質化剤、組成物および使用方法
US6590071B1 (en) 1998-12-10 2003-07-08 University Of Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
WO2002066067A2 (fr) * 2001-02-16 2002-08-29 King's College London Nouveau systeme d'administration de medicaments
WO2002066067A3 (fr) * 2001-02-16 2003-02-13 King S College London Nouveau systeme d'administration de medicaments
EP1663933A4 (fr) * 2003-09-08 2010-10-27 Mirus Bio Corp Transfert ameliore de medicaments par des modifications hydrophobes instables
EP1663933A2 (fr) * 2003-09-08 2006-06-07 Mirus Bio Corporation Transfert ameliore de medicaments par des modifications hydrophobes instables
US20090239790A1 (en) * 2003-12-31 2009-09-24 Chadler Pool Novel recombinant proteins with n-terminal free thiol
WO2008057298A3 (fr) * 2006-10-27 2008-07-03 Wei-Chiang Shen Interféron lipidisé et ses utilisations
US8486384B2 (en) 2006-10-27 2013-07-16 University Of Southern California Lipidized interferon and methods of treating viral hepatitis
US20160009643A1 (en) * 2013-02-28 2016-01-14 Qiaobing Xu Disulfide compounds for delivery of pharmaceutical agents
US9765022B2 (en) * 2013-02-28 2017-09-19 Tufts University Disulfide compounds for delivery of pharmaceutical agents
US20160082126A1 (en) * 2013-05-13 2016-03-24 Tufts University Nanocomplexes for delivery of saporin
US10792328B2 (en) 2013-05-13 2020-10-06 Trustees Of Tufts College Nanocomplexes for delivery of saporin

Also Published As

Publication number Publication date
CA2267179A1 (fr) 1998-04-02
AU737865B2 (en) 2001-09-06
JP2002515883A (ja) 2002-05-28
AU4596797A (en) 1998-04-17
KR20000048608A (ko) 2000-07-25
NO991465L (no) 1999-05-10
CN1235594A (zh) 1999-11-17
BR9712128A (pt) 2000-12-12
CN1127477C (zh) 2003-11-12
EP1023316A2 (fr) 2000-08-02
KR100691315B1 (ko) 2007-03-12
IL129177A0 (en) 2000-02-17
WO1998013007A8 (fr) 1999-05-20
NO991465D0 (no) 1999-03-25
EP1023316A4 (fr) 2004-06-09

Similar Documents

Publication Publication Date Title
US6093692A (en) Method and compositions for lipidization of hydrophilic molecules
EP1327628B1 (fr) Lipidisation de molecules hydrophiles
US5851548A (en) Liposomes containing cationic lipids and vitamin D
US7553830B2 (en) Compositions for the delivery of negatively charged molecules
US5739271A (en) Thiocationic lipids
US5711964A (en) Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
AU737865B2 (en) Methods and compositions for lipidization of hydrophilic molecules
WO1998013007A9 (fr) Procedes et compositions pour la lipidation de molecules hydrophile
CN114716518A (zh) 一种能够抑制pcsk9表达的分子构造及药物组合物
EP0747351A2 (fr) Lipides thiocationiques, compositions pharmaceutiques et leurs méthodes d'utilisation
JP2002501762A (ja) 還元性条件に感受性のトランスフェクション用組成物、該組成物を含有する医薬組成物及びそれらの用途
US5759519A (en) Method for the intracellular delivery of biomolecules using thiocationic lipids
US20190321487A1 (en) Cyclodextrin conjugates
US5756352A (en) Thiocationic lipid-nucleic acid conjugates

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199191.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 13/98, UNDER (30) REPLACE THE EXISTING TEXT BY "08/721306 26.09.96 US 60/049499 13.06.97 US"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1019997002543

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2267179

Country of ref document: CA

Ref document number: 2267179

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/002914

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997944483

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

D17 Declaration under article 17(2)a
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997002543

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997944483

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019997002543

Country of ref document: KR